Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 99, Issue 12, 2005, Pages 1511-1520

  Campbell, Malcolm ^a,g   Eliraz, Abraham ^b   Johansson, Gunnar ^c   Tornling, Göran ^d,e   Nihlén, Ulf ^e   Bengtsson, Thomas ^e   Rabe, Klaus F ^f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b KAPLAN MEDICAL CENTER   (Israel)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NONE   (United Kingdom)

Author keywords

As needed reliever; COPD; Formoterol; Maintenance

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; PLACEBO; TERBUTALINE; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PHARYNGITIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; TREATMENT OUTCOME; TREMOR;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TERBUTALINE; TREATMENT OUTCOME;

EID: 28044433010     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.08.016     Document Type: Article

References (26)

1. GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report, March 2001 [updated 2003].
2. 2-agonists on clinical outcomes in chronic obstructive pulmonary disease J Allergy Clin Immunol 110 Suppl 2002 298-303
3. B.L. Maesen C.J. Westermann V.A. Duurkens et al. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease Eur Respir J 13 1999 1103-1108
4. S.I. Rennard W. Anderson R. ZuWallack et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1087-1092
5. R. Aalbers J. Ayres V. Backer et al. Formoterol in patients with chronic obstructive pulmonary disease - a randomized, controlled, 3-month trial Eur Respir J 19 2002 936-943
6. R. Dahl L.A. Greefhorst D. Nowak et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 778-784
7. D.A. Mahler J.F. Donohue R.A. Barbee et al. Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957-965
8. P.W. Jones T.K. Bosh Quality of life changes in COPD patients treated with salmeterol Am J Respir Crit Care Med 155 1997 1283-1289
9. M. Wadbo C.G. Löfdahl K. Larsson et al. Effects of formoterol and ipratropium bromide in COPD: A 3-month placebo-controlled study Eur Respir J 20 2002 1138-1146
10. M. Cazzola S. Centanni C. Regorda et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD Pulm Pharmacol Ther 14 2001 41-45
11. D. Benhamou A. Cuvelier J.F. Muir et al. Rapid onset of bronchodilation in COPD: A placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk) Respir Med 95 2001 817-821
12. M. Cazzola M.G. Matera G. Santangelo et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: A dose-response study Respir Med 89 1995 357-362
13. P.H. Quanjer G.J. Tammeling J.E. Cotes et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society Eur Respir J 16 Suppl 1993 5-40
14. P.W. Jones F.H. Quirk C.M. Baveystock et al. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire Am Rev Respir Dis 145 1992 1321-1327
15. R.A. Pauwels C.G. Löfdahl D.S. Postma et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405-1411
16. P.M. O'Byrne P.J. Barnes R. Rodriguez-Roisin et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392-1397
17. A.E. Tattersfield C.G. Löfdahl D.S. Postma et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: A randomised trial Lancet 357 2001 257-261
18. M. Cazzola M. D'Amato C. Califano et al. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease Clin Ther 24 2002 595-604
19. M. Cazzola P. Santus M.G. Matera et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD Respir Med 97 2003 458-462
20. W. Boonsawat S. Charoenratanakul C. Pothirat et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma Respir Med 97 2003 1067-1074
21. W. Szafranski A. Cukier A. Ramirez et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74-81 [Erratum in Eur Respir J 2003;21:912]
22. 1 reversibility does not adequately predict effect of formoterol via Aerolizer in chronic obstructive pulmonary disease Int J Clin Pract 58 2004 457-464
23. K.J. Tötterman L. Huhti E. Sutinen et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients Eur Respir J 12 1998 573-579
24. J. Malolepszy G. Böszörményi Nagy O. Selroos et al. Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction Eur Respir J 18 2001 928-934 [Erratum in Eur Respir J 2002 19 384]
25. A. Goldkorn P. Diotto C. Burgess et al. The pulmonary and extra-pulmonary effects of high dose formoterol in COPD: A comparison with salbutamol Respirology 9 2004 102-108
26. J. van der Palen J.J. Klein C.L. van Herwaarden et al. Multiple inhalers confuse asthma patients Eur Respir J 14 1999 1034-1037